tiprankstipranks
Advertisement
Advertisement

KROS Stock Latest News

Hold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16
RatingsHold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16
4d ago
KROS
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
PremiumThe Fly
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
5d ago
KROS
Keros Therapeutics price target lowered to $23 from $30 at Leerink
PremiumThe Fly
Keros Therapeutics price target lowered to $23 from $30 at Leerink
5d ago
KROS
Keros updates TGF-β pipeline strategy in new presentation
PremiumCompany Announcements
Keros updates TGF-β pipeline strategy in new presentation
5d ago
8K
KROS
Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)
PremiumThe Fly
Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)
5d ago
KROS
Keros Therapeutics Earns Milestone Payment for Elritercept Trial
PremiumCompany AnnouncementsKeros Therapeutics Earns Milestone Payment for Elritercept Trial
9d ago
8K
KROS
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Premium
The Fly
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
9d ago
TAK
KROS
Keros Therapeutics Announces CFO Resignation and Interim Successor
Premium
Company Announcements
Keros Therapeutics Announces CFO Resignation and Interim Successor
17d ago
8K
KROS
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
PremiumCompany Announcements
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
1M ago
KROS
Keros Therapeutics Appoints Anne Prener to Board
PremiumCompany Announcements
Keros Therapeutics Appoints Anne Prener to Board
1M ago
8K
KROS
Keros Therapeutics Stockholders Approve Directors and Governance Matters
PremiumCompany Announcements
Keros Therapeutics Stockholders Approve Directors and Governance Matters
2M ago
8K
KROS
Keros Therapeutics CEO to Present at Goldman Sachs Conference
PremiumCompany Announcements
Keros Therapeutics CEO to Present at Goldman Sachs Conference
2M ago
8K
KROS
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
PremiumRatingsHold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
3M ago
KROS
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
Premium
Ratings
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
3M ago
KROS
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
Premium
The Fly
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
3M ago
KROS
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
PremiumRatings
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
5M ago
KROS
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
PremiumCompany Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
5M ago
8K
KROS
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
PremiumThe Fly
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
5M ago
KROS
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
PremiumThe Fly
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
5M ago
KROS
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
PremiumCompany AnnouncementsKeros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
5M ago
KROS
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
Premium
The Fly
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
5M ago
KROS
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
Premium
Company Announcements
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
5M ago
8K
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >